131 related articles for article (PubMed ID: 24373735)
1. Enhancing the pharmacodynamic profile of a class of selective COX-2 inhibiting nitric oxide donors.
Biava M; Battilocchio C; Poce G; Alfonso S; Consalvi S; Di Capua A; Calderone V; Martelli A; Testai L; Sautebin L; Rossi A; Ghelardini C; Di Cesare Mannelli L; Giordani A; Persiani S; Colovic M; Dovizio M; Patrignani P; Anzini M
Bioorg Med Chem; 2014 Jan; 22(2):772-86. PubMed ID: 24373735
[TBL] [Abstract][Full Text] [Related]
2. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
Martelli A; Testai L; Anzini M; Cappelli A; Di Capua A; Biava M; Poce G; Consalvi S; Giordani A; Caselli G; Rovati L; Ghelardini C; Patrignani P; Sautebin L; Breschi MC; Calderone V
Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950
[TBL] [Abstract][Full Text] [Related]
3. Novel analgesic/anti-inflammatory agents: diarylpyrrole acetic esters endowed with nitric oxide releasing properties.
Biava M; Porretta GC; Poce G; Battilocchio C; Alfonso S; Rovini M; Valenti S; Giorgi G; Calderone V; Martelli A; Testai L; Sautebin L; Rossi A; Papa G; Ghelardini C; Di Cesare Mannelli L; Giordani A; Anzellotti P; Bruno A; Patrignani P; Anzini M
J Med Chem; 2011 Nov; 54(22):7759-71. PubMed ID: 21992176
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor.
Imanishi J; Morita Y; Yoshimi E; Kuroda K; Masunaga T; Yamagami K; Kuno M; Hamachi E; Aoki S; Takahashi F; Nakamura K; Miyata S; Ohkubo Y; Mutoh S
Biochem Pharmacol; 2011 Oct; 82(7):746-54. PubMed ID: 21745460
[TBL] [Abstract][Full Text] [Related]
5. Improving the solubility of a new class of antiinflammatory pharmacodynamic hybrids, that release nitric oxide and inhibit cycloxygenase-2 isoenzyme.
Biava M; Battilocchio C; Poce G; Alfonso S; Consalvi S; Porretta GC; Schenone S; Calderone V; Martelli A; Testai L; Ghelardini C; Di Cesare Mannelli L; Sautebin L; Rossi A; Giordani A; Patrignani P; Anzini M
Eur J Med Chem; 2012 Dec; 58():287-98. PubMed ID: 23131542
[TBL] [Abstract][Full Text] [Related]
6. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
Velázquez C; Praveen Rao PN; Knaus EE
J Med Chem; 2005 Jun; 48(12):4061-7. PubMed ID: 15943479
[TBL] [Abstract][Full Text] [Related]
7. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
Muscará MN; McKnight W; Asfaha S; Wallace JL
Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192
[TBL] [Abstract][Full Text] [Related]
8. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
Song Y; Connor DT; Doubleday R; Sorenson RJ; Sercel AD; Unangst PC; Roth BD; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1151-60. PubMed ID: 10197959
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
[TBL] [Abstract][Full Text] [Related]
11. Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
Hayashi S; Ueno N; Murase A; Nakagawa Y; Takada J
Eur J Med Chem; 2012 Apr; 50():179-95. PubMed ID: 22373734
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity.
Ndengele MM; Cuzzocrea S; Esposito E; Mazzon E; Di Paola R; Matuschak GM; Salvemini D
FASEB J; 2008 Sep; 22(9):3154-64. PubMed ID: 18497304
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal anti-inflammatory drugs and gastric mucosal responses.
Takeuchi K; Suzuki K; Yamamoto H; Araki H; Mizoguchi H; Ukawa H
J Physiol Pharmacol; 1998 Dec; 49(4):501-13. PubMed ID: 10069692
[TBL] [Abstract][Full Text] [Related]
15. Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies.
Abdellatif KR; Chowdhury MA; Dong Y; Das D; Yu G; Velázquez C; Suresh MR; Knaus EE
Bioorg Med Chem; 2009 Jul; 17(14):5182-8. PubMed ID: 19500994
[TBL] [Abstract][Full Text] [Related]
16. A Series of COX-2 Inhibitors Endowed with NO-Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis.
Consalvi S; Poce G; Ragno R; Sabatino M; La Motta C; Sartini S; Calderone V; Martelli A; Ghelardini C; Di Cesare Mannelli L; Biava M
ChemMedChem; 2016 Aug; 11(16):1804-11. PubMed ID: 27229194
[TBL] [Abstract][Full Text] [Related]
17. Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: synthesis, cyclooxygenase inhibition, and nitric oxide release studies.
Abdellatif KR; Chowdhury MA; Dong Y; Chen QH; Knaus EE
Bioorg Med Chem; 2008 Mar; 16(6):3302-8. PubMed ID: 18096394
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and structure-activity relationship studies of novel and diverse cyclooxygenase-2 inhibitors as anti-inflammatory drugs.
Hayashi S; Ueno N; Murase A; Takada J
J Enzyme Inhib Med Chem; 2014 Dec; 29(6):846-67. PubMed ID: 24517373
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
20. NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
Konturek PC; Kania J; Burnat G; Hahn EG
J Physiol Pharmacol; 2006 Dec; 57 Suppl 12():15-24. PubMed ID: 17244951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
